ClinicalTrials.gg
Active, not recruitingNCT06966453Updated Nov 5, 2026

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

A Phase 1/2 interventional study of Disitamab vedotin in Breast Cancer and Breast Neoplasms, sponsored by Pfizer. Active, not recruiting at 145 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Pfizer · Phase 1/2, Interventional, and Treatment

Updated Nov 5, 20263 sites added25 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
74
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing disitamab vedotin in Breast Neoplasms — 11 open to participants now, 14 under way, 5 of them phase 3. disitamab vedotin · Breast Neoplasms.

Enrollment
8th of 17
74 · median 64
Started
2025
the only one that year
Phase 1/2
2 of 17
none open now
Primary completion
2027-10
later than 8 of 13 live
Registered
15th of 17
by date
Lead sponsor
1 of 17
Pfizer

Among the 17 studies testing disitamab vedotin in Breast Neoplasms, this one is the 8th largest by enrollment, is the only one that started in 2025, is one of 2 in phase 1/2, reaches primary completion later than 8 of the 13 other live ones, and was the 15th registered.

Breast Neoplasms

14,840 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

11 of the 17 studies testing disitamab vedotin in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About disitamab vedotin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,398 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 590 (25%) stop at 75 or younger; 103 take children under 18; 213 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing disitamab vedotin in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this clinical study is to learn about the safety and effects of the study medicine (called disitamab vedotin) for the possible treatment of people with breast cancer that is hard to treat and has spread in the body (advanced cancer).

This study is seeking participants who:

  • have breast cancer that is hard to treat and has spread in the body (advanced cancer)
  • have tumors that have HER2 on them
  • have received previous treatment for their advanced breast cancer

All participants in this study will receive disitamab vedotin at the study clinic once every 2 weeks as an intravenous (IV) infusion (given directly into a vein).

Participants will take the study medicine until they or their doctor decides to stop. This might be because their cancer is getting worse, the study medicine is no longer helping, they have bad side effects, or they wish to stop taking the study medicine. During this time, the participants will have study visits every 2 weeks. After the participants have stopped taking the study medicine, they will have follow-up visits about every 6 weeks unless their cancer gets worse. After that, they will have follow-up phone calls about every 12 weeks.

The study team will look at the experiences of people receiving the study medicine. This will help the study team decide if the study medicine is safe and effective.

03

Conditions studied

  • Breast Cancer
  • Breast Neoplasms

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed diagnosis of locally-advanced, unresectable, or breast carcinoma.
  • Human epidermal growth factor receptor 2 () and hormone receptor (HR) status appropriate for enrollment in cohort.
  • HER2 status determined by most recent local assessment based on American Society of Clinical Oncology (ASCO) and College of American Pathologists (CAP) guidelines for assessment of HER2 in BC for interpretation of HER2 expression and amplification
  • HER2+: immunohistochemistry (IHC) 3+ or IHC 2+/in situ hybridization (ISH)+
  • HER2-low: IHC 1+/ISH-negative or untested or IHC 2+/ISH-negative
  • HER2-ultralow: IHC 0 with membrane staining (any staining of the membrane in >0 and ≤10% of cancer cells) o HR+ disease is determined as either estrogen receptor (ER) and/or progesterone receptor (PgR) positive [ER or PgR ≥1%]) and HR negative disease is determined as both ER and PR negative [ER and PgR \<1%]) per ASCO/CAP guidelines in the advanced disease setting. If a patient has had multiple ER/PgR results for advanced disease, the most recent test result will be used to confirm eligibility.

Prior therapy requirements for Cohort 1 (HER2+, HR+ or HR- participants):

  • Received prior trastuzumab, pertuzumab and a taxane if available as local standard of care therapy for advanced disease.
  • Prior tucatinib based therapy is allowed.
  • Must have progression on or after, or be intolerant to, T-DXd in any line advanced disease setting.
  • No more than 3 prior systemic cytotoxic therapy regimens (including antibody drug conjugates [ADCs]) for Locally Advanced (LA)/metastatic breast cancer (mBC). Participants previously treated with (neo) cytotoxic therapy and have disease within 6 months of cytotoxic treatment is considered to have received 1 line of cytotoxic therapy for LA/mBC.

Prior therapy requirements for Cohort 2 (HR+/HER2-low participants):

  • No more than 3 prior systemic cytotoxic therapy regimens (including ADCs) for LA/mBC. Participants previously treated with (neo)adjuvant cytotoxic therapy and have disease relapsed within 6 months of cytotoxic treatment is considered to have received 1 line of cytotoxic therapy for LA/mBC.
  • Participants with known germline breast cancer gene (BRCA) mutation must have received a poly-ADP ribose polymerase (PARP) inhibitor, where available and not medically .
  • Must have progression on or after, or be intolerant to, trastuzumab deruxtecan (T-DXd) in any line advanced disease setting.
  • Must have intolerance to endocrine therapy (ET) or ET refractory disease:
  • Progressed on ≥2 lines of ET for LA/mBC AND had received a cyclin-dependent kinase (CDK)4/6 inhibitor in the adjuvant or metastatic setting if available as local standard of care and not contraindicated.

OR

  • Progressed on 1 line of ET for LA/mBC AND had a relapse while on adjuvant ET after definitive surgery for primary tumor AND had received a cyclin-dependent kinase (CDK) 4/6 inhibitor in the adjuvant or advanced setting if available as local standard of care and not contraindicated.

Prior therapy requirements for Cohort 3 (HR+/HER2-ultralow or HR-/HER2-low [HER2 low TNBC] participants):

  • No more than 4 prior systemic cytotoxic chemotherapy regimens (including ADCs) for advanced or mBC. Participants previously treated with (neo)adjuvant cytotoxic therapy and have disease relapsed within 6 months of cytotoxic treatment is considered to have received 1 line of cytotoxic therapy for LA/mBC.
  • Known germline BRCA mutation must have received a PARP-inhibitor if available as local standard of care therapy and not medically contraindicated.
  • Prior sacituzumab govitecan is allowed.
  • Prior T-DXd is allowed.
  • Participants with HR negative (TNBC), HER2-low and programmed cell death receptor ligand 1 ()-positive (combined positive score [CPS] ≥10) tumors must have received pembrolizumab (or other PD-L1 inhibitor) with chemotherapy if available as local standard of care therapy and not medically contraindicated.
  • Participants with HR+/HER2-ultra low tumors must have received at least 1 antihormonal therapy in any setting or be ineligible for ET.
  • Participants with HR+/HER2-ultra low tumors must have had prior therapy with a CDK4/6 inhibitor in the adjuvant or advanced setting.

Exclusion criteria

Exclusion Criteria:

  • Known to any contained in the drug formulation of disitamab vedotin.
  • Active central nervous system (CNS) and/or .
  • Participants with a history of other invasive within 3 years before the Cycle 1 Day 1 (C1D1) of study intervention, or any evidence of residual disease from a previously diagnosed malignancy.
  • Prior therapy with ADCs with MMAE payload.
  • Participants who have received prior systemic anticancer treatment or radiotherapy within 2 weeks, or 5 half-lives, whichever is shorter, prior to C1D1 of study intervention. Note: If the last immediate anticancer treatment contained an antibody-based agent(s), then an interval of 28 days or 5 half-lives (whichever is shorter) of the agent(s) prior to receiving the study intervention treatment is required.

    • Participants must have recovered from all adverse events due to previous therapies.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    Cohort 2: HR+, HER2-low locally advanced or metastatic breast cancer

    disitamab vedotin monotherapy

    Drug: Disitamab vedotin

  • Experimental
    Cohort 1: HER2+ locally advanced or metastatic breast cancer

    disitamab vedotin monotherapy

    Drug: Disitamab vedotin

  • Experimental
    Cohort 3: HR+, HER2 ultra-low or HR-negative, HER2-low locally advanced or metastatic breast cancer

    disitamab vedotin monotherapy

    Drug: Disitamab vedotin

Interventions

  • Given into the vein (IV; intravenous) every 2 weeks.

    Also known as: RC48, RC48-ADC

06

What researchers measure

Primary outcomes

  1. Objective response (OR) by investigator assessment

    The primary endpoint OR by investigator assessment is defined as the proportion of participants with confirmed CR or PR as determined by investigator per RECIST Version 1.1.

    Time frame: From Cycle 1 Day 1 until disease progression by investigator assessment per RECIST version 1.1, or death due to any cause, whichever is earlier; up to approximately 2 years

Secondary outcomes

  1. Duration of response (DOR) per RECIST v1.1 by investigator assessment

    DOR by investigator assessment is defined as the time from first documentation of objective response (CR or PR) by investigator assessment per RECIST version 1.1 that is subsequently confirmed, to the first documentation of progressive disease or to death due to any cause, whichever comes first.

    Time frame: From first documentation of objective response (CR or PR) by investigator assessment per RECIST version 1.1 that is subsequently confirmed, to the first documentation of progressive disease or to death due to any cause; up to approximately 2 years

  2. Disease control rate (DCR) (confirmed CR, confirmed PR, and stable disease) per RECIST v1.1 by investigator assessment

    DCR by investigator assessment is defined as the proportion of participants with CR or PR with confirmation, or Stable Disease (SD) by investigator assessment per RECIST version 1.1.

    Time frame: From Cycle 1 Day 1 until disease progression by investigator assessment per RECIST version 1.1, or death due to any cause, whichever is earlier; up to approximately 2 years

  3. Progression-free survival (PFS) per RECIST v1.1 by investigator assessment

    PFS by investigator assessment is defined as the time from C1D1 to the first documentation of disease progression as determined by investigator per RECIST version 1.1, or to death due to any cause, whichever comes first.

    Time frame: From Cycle 1 Day 1 until disease progression by investigator assessment per RECIST version 1.1, or death due to any cause, whichever is earlier; ; up to approximately 2 years

  4. Overall survival (OS)

    OS is defined as the time from C1D1 to date of death due to any cause.

    Time frame: From Cycle 1 Day 1 until death due to any cause; up to approximately 3 years

  5. PK Parameter: Serum Concentrations of disitamab vedotin, total antibody, and unconjugated MMAE

    The Antibody-drug conjugate (TAb), and unconjugated Monomethyl auristatin E (MMAE) concentrations for disitamab vedotin summarized at each PK sampling time point.

    Time frame: From Cycle 1 Day 1 to end of treatment; up to approximately 2 years

  6. Incidence of anti-drug antibodies (ADA) against disitamab vedotin

    The percentage of participants with positive ADA will be summarized.

    Time frame: From Cycle 1 Day 1 to end of treatment; up to approximately 2 years

  7. Incidence of Adverse Events (AE) and Serious Adverse Events (SAE)

    Type, incidence, severity, seriousness, and relatedness of AEs. Type, incidence, and severity of laboratory abnormalities and significant changes from baseline.

    Time frame: Up to approximately 2 years

07

Study locations

145 sites

Showing the first 100 of 145 sites across 9 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Oct 2027, 27 months after the start.

Of 163 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's planned 27 months is below that.

Counting every sponsor, half of 330 studies reached it within 62 months; a quarter within 45 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2025
First posted
May 11, 2025
StartActual
Jun 30, 2025
Primary completionEst.
Oct 25, 2027
CompletionEst.
Jan 27, 2030
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added, 25 sites removed
Show 3 added (2 United States, 1 Germany)
  • Florida Cancer Specialists · West Palm Beach, United States
  • Virginia Cancer Specialists, PC · Woodbridge, United States
  • Universitätsklinikum Heidelberg · Heidelberg, Germany
Show 25 removed
  • Stanford Cancer Center Emeryville · Emeryville, United States
  • Stanford Cancer Center Pleasanton · Pleasanton, United States
  • Stanford Healthcare - Portola Valley · Portola, United States
  • Stanford University Cancer Center South Bay · San Jose, United States
  • Winship Cancer Institute @ Emory University Hospital Midtown · Atlanta, United States
  • Emory Clinic Investigational Drug Services · Atlanta, United States
  • Emory University Hospital · Atlanta, United States
  • Winship Cancer Institute · Atlanta, United States
  • Swedish Cancer Institute · Seattle, United States
  • Swedish Medical Center · Seattle, United States
  • Lakeridge Health · Oshawa, Canada
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico di Sant'Orsola · Bologna, Italy
  • Parc de Salut Mar - Hospital del Mar · Barcelona, Spain
  • Florida Cancer Specialists · West Palm Beach, United States
  • Texas Oncology - San Antonio · San Antonio, United States
  • Texas Oncology - San Antonio · San Antonio, United States
  • Oncology & Hematology Associates of Southwest Virginia Inc dba Blue Ridge Cancer Care · Blacksburg, United States
  • Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care · Low Moor, United States
  • Oncology & Hematology Associates of Southwest Virginia Inc dba Blue Ridge Cancer Care · Roanoke, United States
  • Oncology & Hematology Associates of Southwest Virginia Inc dba Blue Ridge Cancer Care · Salem, United States
  • Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care · Wytheville, United States
  • Universitätsklinikum Heidelberg · Heidelberg, Germany
  • Kanagawa cancer center · Yokohama, Japan
  • Hospital Universitario Virgen de la Victoria · Málaga, Spain
  • Hospital Universitario Virgen Nieves · Granada, Spain
across 2 updates, Oct 13, 2026 – Nov 5, 2026
Show all 2 updates
  1. Nov 5, 2026
    12 sites removed
    Show 12 removed
    • Florida Cancer Specialists · West Palm Beach, United States
    • Texas Oncology - San Antonio · San Antonio, United States
    • Texas Oncology - San Antonio · San Antonio, United States
    • Oncology & Hematology Associates of Southwest Virginia Inc dba Blue Ridge Cancer Care · Blacksburg, United States
    • Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care · Low Moor, United States
    • Oncology & Hematology Associates of Southwest Virginia Inc dba Blue Ridge Cancer Care · Roanoke, United States
    • Oncology & Hematology Associates of Southwest Virginia Inc dba Blue Ridge Cancer Care · Salem, United States
    • Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care · Wytheville, United States
    • Universitätsklinikum Heidelberg · Heidelberg, Germany
    • Kanagawa cancer center · Yokohama, Japan
    • Hospital Universitario Virgen de la Victoria · Málaga, Spain
    • Hospital Universitario Virgen Nieves · Granada, Spain
    + 1 other change: verification date
  2. Oct 13, 2026
    3 sites added, 13 sites removed
    Show 3 added (2 United States, 1 Germany)
    • Florida Cancer Specialists · West Palm Beach, United States
    • Virginia Cancer Specialists, PC · Woodbridge, United States
    • Universitätsklinikum Heidelberg · Heidelberg, Germany
    Show 13 removed
    • Stanford Cancer Center Emeryville · Emeryville, United States
    • Stanford Cancer Center Pleasanton · Pleasanton, United States
    • Stanford Healthcare - Portola Valley · Portola, United States
    • Stanford University Cancer Center South Bay · San Jose, United States
    • Winship Cancer Institute @ Emory University Hospital Midtown · Atlanta, United States
    • Emory Clinic Investigational Drug Services · Atlanta, United States
    • Emory University Hospital · Atlanta, United States
    • Winship Cancer Institute · Atlanta, United States
    • Swedish Cancer Institute · Seattle, United States
    • Swedish Medical Center · Seattle, United States
    • Lakeridge Health · Oshawa, Canada
    • IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico di Sant'Orsola · Bologna, Italy
    • Parc de Salut Mar - Hospital del Mar · Barcelona, Spain
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06966453
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 11, 2025
Start date
Jun 30, 2025
Primary completion
Oct 25, 2027 (estimated)
Completion
Jan 27, 2030 (estimated)
Last update
Nov 5, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Disitamab vedotin

Start the discussion